Find Academic Supervisors

• Bioengineering
• Systems Glycobiology
• Thrombosis & Hemostasis
• +3 more

Sriram Neelamegham is the UB Distinguished Professor of Chemical & Biological Engineering, Biomedical Engineering, and Medicine at the University at Buffalo, SUNY. His research focuses on applying engineering principles to study molecular mechanisms of blood cell interactions in diseases such as inflammation, thrombosis, and cancer. He leads the Bioengineering Laboratory within the School of Engineering and Applied Sciences. Education: PhD in Chemical/Biomedical Engineering, Rice University, 1996 B.Tech in Chemical Engineering, Indian Institute of Technology Delhi, 1991 Research Interests: Systems Glycobiology: Investigating glycan biosynthesis and its role in disease Leukocyte and Platelet Adhesion Dynamics under Fluid Flow Von Willebrand Factor (VWF) Structure-Function Relationships Engineering Glycoengineered Therapeutics and Diagnostic Tools Key Contributions: Developed computational models and experimental tools for glycosylation pathway analysis Discovered mechanisms of VWF conformational changes under shear stress Pioneered glycoengineering strategies for stem cell targeting Awards & Recognition: NIH Independent Scientist Award (2015) SUNY Chancellor's Award for Excellence (2015) AIMBE Fellow (2012) and BMES Fellow (2019) 2018 Schoellkopf Medal (ACS) Lab Activities: Recruitment of postdocs, full-time, and part-time research technicians Development of glycan-engineered technologies for drug delivery and diagnostics Collaborations with biomedical industries and academic institutions

Melanie WilkeView profile

Professor

• Cognitive Neurology
• Neural Mechanisms of Perception
• Visual Consciousness
• +12 more

Professor Melanie Wilke is a leading figure in cognitive neurology at the University Medical Center Göttingen, where she serves as Director of the Department of Cognitive Neurology and Head of the MR Research Unit. She is also a Co-Investigator in the 'Decision and Awareness' group at the German Primate Center. Her work bridges human and non-human primate neuroscience to investigate the neural basis of perception, awareness, and movement planning. Her research focuses on understanding how distributed neural activity supports spatial awareness and decision-making. Key areas include thalamocortical interactions, neural mechanisms of spatial neglect, and translational models of cognitive disorders. She employs multimodal methods such as fMRI, electrophysiology, brain stimulation (tACS, tDCS, TMS), and inactivation techniques in both human and monkey models. Analysis of her recent publications reveals a strong emphasis on visual consciousness, neural connectivity, and sensorimotor integration. Her work frequently explores the role of the pulvinar and parietal cortex in attention and awareness, using innovative paradigms including no-report tasks and microstimulation. There is a clear translational trajectory from basic mechanisms to clinical applications in stroke and Parkinson’s disease. Fellows Award for Excellence in Biomedical Research, National Institutes of Health, USA (2008) Prof. Wilke leads a dynamic research group and mentors students within several graduate programs, including Systems Neuroscience and the International Max Planck Research School (IMPRS). Her team conducts cutting-edge research using advanced imaging and stimulation techniques. She has secured long-term support through the Herman and Lilly Schilling Foundation Professorship (2011–2022) and continues to lead major projects in cognitive neurology and brain network dynamics. Her laboratory, embedded in the Heart & Brain Center Göttingen, fosters interdisciplinary collaboration and focuses on developing novel therapeutic interventions for cognitive deficits following brain injury. The MR Research Unit under her leadership is central to advancing non-invasive brain imaging and stimulation in both research and clinical contexts.

David BoocockView profile

Academic

• Proteomics
• Biomarker Discovery
• Cancer Research
• +8 more

Dr. David Boocock is a Senior Research Fellow and Group Leader of the Biological Mass Spectrometry and Clinical Proteomics group at the John van Geest Cancer Research Centre, Nottingham Trent University. He joined NTU in 2007 as a Research Fellow and became Senior Research Fellow in 2009, establishing the quantitative LC-MS facility for biological research. His work spans biomarker discovery, cancer research (prostate, breast, melanoma, ovarian, and LAM), Alzheimer's disease, diabetes, and COPD, utilizing advanced proteomics and metabolomics techniques. Senior Research Fellow, Biological Mass Spectrometry and Clinical Proteomics Group John van Geest Cancer Research Centre, Nottingham Trent University Established quantitative mass spectrometry facility in 2013/14 His research focuses on proteomics and biomarker discovery across multiple disease contexts, with particular emphasis on cancer progression and therapeutic response. He employs SWATH Acquisition, LC-MS/MS, and multiomics approaches to analyze protein expression patterns. Collaborations include SCIEX, Ludwig-Maximilians-Universität München, and University of Debrecen. Recent publications highlight his work on chronic kidney disease biomarkers (2025), prostate cancer metastasis mechanisms (2024), and transglutaminase biology in neurodegenerative and metabolic diseases. He supervises PhD students and contributes to undergraduate teaching in cancer and proteomics topics.

ONG Choon NamView profile

Professor

• Metabolomics
• Biomarkers
• Environmental Health

ONG Choon Nam is a Professor at the Saw Swee Hock School of Public Health , National University of Singapore (NUS), and a Principal Investigator at the NUS Environmental Research Institute (NERI). With over 330 peer-reviewed publications and an h-index of 84, his work bridges Metabolomics , Biomarkers , and Environmental Health . B.Sc (1972), Nanyang University MSc (1974), University of London PhD (1977), University of Manchester His research focuses on metabolomics for environmental health assessments, biomarker discovery, and toxicology. He has pioneered studies on nanoparticle toxicity, dietary metabolites, and water quality, with contributions to NEWater and soya waste valorization . The 15 most recent articles highlight trends in toxicology , environmental health , and agricultural sustainability , with methods spanning mass spectrometry , metabolite profiling , and nanotoxicity studies. His work often integrates multi-omics and biomarker analysis across diverse species. Scientific Awards : AstraZeneca International Award (2002) Public Service Medal (2004) Outstanding Mentor Award (2016) Research Excellence Award (2008) Public Administration Medal (2016) ONG has served on international advisory panels for the WHO, CDC China, and the US National Research Council, while leading administrative roles at NUS, including Director of the Environmental Research Institute (2009–2018). His interdisciplinary collaborations span nano-toxicology , water quality , and dietary health effects .

• Gene Therapy
• Paediatric Immunology
• Immunology
• +4 more

Claire Booth is Professor of Gene Therapy and Paediatric Immunology within the Infection, Immunity & Inflammation Department at University College London. Her work bridges cutting-edge gene therapy techniques with clinical applications for pediatric immunodeficiency disorders, focusing on translating laboratory discoveries into therapeutic interventions for rare genetic conditions. Education: Doctor of Philosophy, University College London (2012) Master of Science, University College London (2007) Bachelor of Medicine/Bachelor of Surgery, King's College London (2001) Professor Booth's research centers on gene therapy approaches for inborn errors of immunity, with particular expertise in lentiviral vector systems, hematopoietic stem cell gene therapy, and genome editing techniques. Her work addresses critical challenges in treating rare immunodeficiency disorders including X-linked SCID, Fanconi anemia, leukocyte adhesion deficiency, and CTLA4 insufficiency. She investigates both the mechanistic underpinnings of these disorders and the development of novel therapeutic strategies that can be translated to clinical practice. Analysis of her recent publications (2023-2024) reveals a strong focus on clinical translation of gene therapy approaches, with numerous phase 1/2 clinical trial results, methodological improvements in conditioning regimens, and exploration of novel targets for immunodeficiency disorders. Her work spans basic science investigations through to clinical implementation, with particular attention to safety profiles, immune reconstitution patterns, and long-term outcomes in pediatric patients. Professor Booth actively collaborates with international research groups and clinical networks, contributing to consensus guidelines for managing rare immunological conditions. Her research program addresses critical gaps in understanding how to effectively deliver gene therapies for rare diseases while navigating the complex challenges of commercialization and accessibility.

Steven D LeachView profile

Professor

• Pancreatic Cancer Biology
• Cancer Development and Tumorigenesis
• Molecular and Systems Biology
• +8 more

Steven D. Leach is Professor of Molecular and Systems Biology, Surgery, and Medicine at the Geisel School of Medicine at Dartmouth, where he also holds the Preston T. and Virginia R. Kelsey Distinguished Chair in Cancer and serves as Director of the Dartmouth Cancer Center (Norris Cotton Cancer Center). He has previously held leadership and faculty positions at Memorial Sloan Kettering and Johns Hopkins University. MD, Emory University BS in Biology, Princeton University (with high honors) Additional training at Yale and MD Anderson Dr. Leach's research is centered on pancreatic cancer biology, with a focus on understanding early tumorigenic events through developmental and molecular pathways. His lab utilizes mouse and zebrafish models to investigate epithelial plasticity, oncogenic signaling (particularly Notch and Kras), immune responses, and clonal evolution in pancreatic neoplasia. His work has revealed key mechanisms linking pancreatic development to cancer, including the role of acinar cells as cells of origin and the discovery of unique immune neoepitopes in long-term survivors. The selected publications, spanning from 2003 to 2017, reflect a sustained focus on the molecular and immunological underpinnings of pancreatic cancer. Themes include oncogenic signaling (Notch, Kras), tumor microenvironment interactions, epithelial-mesenchymal transition, and immune neoantigen landscapes. These works, published in top journals like Nature and Cell , demonstrate a trajectory from mechanistic discovery to translational immunology. Fellow of the American Association for the Advancement of Science (AAAS), 2019 Robert Woodruff Fellow, Emory University Dr. Leach has a strong record of mentorship, having trained 32 graduate students and postdoctoral fellows, many of whom have achieved independent faculty positions and NIH funding. He has been the principal investigator on numerous NIH grants, including R01, P01, P30, U01, S10, and T32 awards, supporting both research and training initiatives. His lab currently includes research scientists, graduate students, and postdoctoral associates engaged in projects on mRNA splicing, chromatin dynamics, and clonal evolution. The Leach Laboratory is an active research group within the Dartmouth Cancer Center, focusing on translational pancreatic cancer research. Lab members include graduate students from the Molecular and Cellular Biology program, postdoctoral researchers, and research scientists, working collaboratively on projects that bridge basic science and clinical applications. The lab utilizes advanced model systems and genomic technologies to uncover fundamental mechanisms of cancer initiation and progression.

Mark D. NobleView profile

Professor

• Stem Cell Biology
• Neuroscience
• Oncology
• +6 more

Mark D. Noble is a pioneering Professor (Part-Time) in the Department of Biomedical Genetics at the University of Rochester School of Medicine , with concurrent appointments in Neurology, Neurobiology and Anatomy. He co-discovered the first CNS precursor cell in 1983 and directs the University of Rochester Stem Cell and Regenerative Medicine Institute . His career spans institutions including Stanford University and University College London. Ph.D., Genetics, Stanford University (1977) B.S., Biology & Philosophy, Franklin & Marshall College (1971) Post-doctoral: MRC Neuroimmunology Project, University College London (1977-1981) Research Focus : Dr. Noble's work bridges stem cell biology , neuroscience , and oncology . His lab discovered the redox/Fyn/c-Cbl pathway , revealing how oxidative states regulate stem cell function and cancer progression. Key contributions include chemobrain mechanisms , lysosomal dysfunction therapies , and pharmacological approaches for nerve injuries. His team developed 4-aminopyridine applications for nerve repair and diagnosis. Collaborative Impact : Working with Drs. Chris Proschel and Margot Mayer-Pröschel, he advanced astrocyte transplantation for spinal cord and Parkinson's injury. His work on cancer stem cells in glioblastoma and basal-like breast cancer identified novel therapeutic targets through Cool-1/β-pix inhibition of c-Cbl. Patents & Mentorship : Dr. Noble holds 15 patents and consults for biotech companies. His lab has mentored graduate students like Ludia Pack , Yunpeng Pang , and Neal Shah , while driving research on metabolic regulation of stem cells and translational medicine .

• Pharmacology
• Cholesterol Metabolism
• Alzheimer's Disease
• +5 more

Bianca Papotti is a fixed-term Researcher at the Department of Food and Pharmaceutical Sciences, University of Parma. Her academic career spans interdisciplinary research in Pharmacology Cholesterol Metabolism Neurodegenerative Diseases Cardiovascular Pathology Immunometabolism . She teaches courses including Experimental Pharmacology and Food Toxicology. Her research focuses on the role of PCSK9 and cholesterol efflux in Alzheimer's Disease Atherosclerosis Rheumatoid Arthritis Lipoprotein Biology Inflammatory Disease Drug Development . Key trends in her publications (3 in 2025, 12 in 2024) reveal strong emphasis on PCSK9 inhibition mechanisms, cholesterol-immune crosstalk in rheumatoid arthritis, and fasting interventions in lipid-related pathologies. Her work has explored PCSK9's neuroinflammatory effects ABCA1/ABCG1 transporter dynamics Macrophage cholesterol loading Natural compound screening HDL dysfunction in diabetes Covid-19 lipid interactions .

Luke MarshView profile

Associate Professor

• Criminal Law
• Criminal Procedure
• Plea Bargaining
• +3 more

Luke Marsh is an Associate Professor at the Faculty of Law, The Chinese University of Hong Kong (CUHK), where he teaches criminal law and criminal procedure. He serves as Deputy Director of the Juris Doctor (JD) Programme, supervises the Faculty’s Clinic Programme, and instructs Trial Advocacy for the Postgraduate Certificate in Laws (PCLL). A former criminal barrister in the UK, Marsh has represented clients across all major courts including the Court of Appeal and worked on high-profile international cases at the UN International Criminal Tribunal for the Former Yugoslavia. His educational background includes: MSt International Human Rights Law (Oxford) LL.M (Northumbria, Distinction) LL.B (Hons) (King’s College London) Barrister of England and Wales Marsh’s research critically examines the erosion of adversarial justice in criminal systems, with groundbreaking work on plea bargaining and judicial independence. His monograph The Myth of Judicial Independence (Oxford University Press, 2020) challenged foundational assumptions about judicial autonomy, while the Research Handbook on Plea Bargaining (Edward Elgar, 2024) established him as a global authority on negotiated justice. He pioneers clinical legal education in Asia, developing innovative programs that address unmet legal needs in Hong Kong’s refugee community and foster civic engagement through law. Recent scholarship analyzes systemic crises including Covid-19’s impact on criminal courts, police corruption, and refugee rights. His 15 most recent publications reveal three dominant trends: (1) pandemic-induced collapse of criminal justice procedures, (2) strategic use of human rights frameworks in marginalized communities, and (3) global expansion of plea bargaining threatening due process. His awards include: Faculty Award for Academic Impact in Legal Scholarship (2024) CUHK Young Researcher Award (2022) CUHK Research Excellence Award (2018-19) Baron Dr Ver Heyden De Lancey Prize (top Bar Exam performance) Hague Bursary from Middle Temple Marsh actively mentors students through the Clinic Programme, providing hands-on training in refugee advocacy and trial skills. He has represented asylum seekers via Justice Centre Hong Kong and advised the Legislative Council on refugee policy. His global research network spans Columbia University, UCLA, Oxford, and the British Institute of International and Comparative Law, where he investigates cross-jurisdictional justice innovations. Current projects include analyzing coerced guilty pleas in common law systems and developing clinical models for Asian legal education.

Thea TlstyView profile

Professor

• Epithelial-stromal interactions
• Genomic instability
• Chronic inflammation and cancer
• +3 more

Dr. Thea Tlsty is a Professor at the University of California San Francisco (UCSF) School of Medicine, Department of Pathology. With over 25 years of experience in cancer biology, she leads multidisciplinary research on epithelial-stromal interactions, chronic inflammation, and cellular plasticity in carcinogenesis. Her lab developed the first biomarkers for ductal carcinoma in situ risk stratification and discovered rare pluripotent cells in normal tissues with implications for metaplastic cancers. Education: BS in Zoology (University of South Florida, 1973) PhD in Molecular Biology (Washington University, 1980) Predoctoral Fellow (Washington University, 1976-1980) Postdoctoral Fellow & Senior Research Associate (Stanford University, 1981-1985) Dr. Tlsty's research focuses on: Stromal-epithelial stress response mechanisms Chronic inflammation's role in cancer CD36 repression in high mammographic density Pluripotent cell biology Multi-investigator grant projects Her 15 most recent publications highlight trends in proteomics, spatial transcriptomics, and multi-omics integration to study tumor microenvironment dynamics, particularly in breast, esophageal, and colorectal cancers. Scientific Awards: Cancer Research UK Grand Challenge Grant (£20M) NCI Outstanding Investigator Award Blaffer Distinguished Lectures (MD Anderson) Nakahara Award (Princess Takamatsu Foundation) KOMEN Scholar & AVON Scholar Elected AAAS Fellow NCI Knudson Award Dr. Tlsty has received continuous NIH funding since 1987, including ongoing R35 grant (R35CA197694) for studying stress-associated cellular plasticity. Her lab's translational insights bridge basic discoveries with clinical applications for cancer prevention and therapy.

Christopher A. J. RomanView profile

Associate Professor

• Immunology
• B Cell Biology
• Autoimmune Diseases
• +3 more

Christopher A. J. Roman serves as Associate Professor and Chairman of Cell Biology at SUNY Downstate Health Sciences University's College of Medicine, with a dual appointment as Associate Professor of Medicine. His career spans over three decades with continuous contributions to immunology and lymphocyte biology. His academic credentials include: B.A. in Biochemistry from Harvard University (1984) Ph.D. in Biological Chemistry from UCLA (1991) Post-Doctoral Fellowships at The Rockefeller University (1992-1994) and MIT (1994-1998) Roman's research centers on B lymphocyte biology with critical focus on immunological tolerance mechanisms preventing autoimmune diseases like systemic lupus erythematosus (SLE). His laboratory investigates transcriptional regulation through Mitf family factors (Mitf, TFE3, TFEB) in lymphocyte function and lipid metabolism pathways involving SMS2 in germinal center tolerance. Employing transgenic mouse models, primary cell cultures, flow cytometry, and immunohistochemistry, his work bridges molecular mechanisms with clinical applications in autoimmunity. Collaborations with Rheumatology and Allergy/Immunology divisions enable direct clinical translation of findings. Analysis of his publication history reveals consistent progression from foundational B cell development studies to current mechanistic investigations of tolerance pathways, with increasing emphasis on transcriptional networks and metabolic regulation in autoimmune pathogenesis. His distinguished recognition includes: LGBTQ+ Advocacy Award (2024) Outstanding Educator in Foundations of Medicine (2018) Excellence in Mentoring Award (2018) SUNY Chancellor's Award for Faculty Service (2008) Lupus Research Institute Novel Project Award (2006) Henry Kunkel Society membership (since 2010) Roman maintains active mentorship of graduate students including MD/PhD candidates Milena Rodriquez (2023), Nanda Lahiri (2020), and Abhimanyu Amarnani (2020). His research program receives sustained funding from NIH institutes (NIAID, NIAMS, ORWH), Lupus Research Alliance, and Lupus Foundation of America. Current collaborative projects with Dr. Chongmin Huan explore SMS2 pathways for lupus therapeutics. He directs a specialized laboratory investigating B cell tolerance mechanisms while leading institutional initiatives including Pathways HEAL (Health Equity Advocacy Leadership) and LGBTQIA+ Health programs.

• Bioimaging
• Bioluminescence
• Molecular Biology
• +4 more

Takeharu Nagai is a Professor at Hokkaido University's Research Institute for Electronic Science, leading the Nagai Laboratory in the Department of Biomolecular Science and Engineering. His research integrates bioimaging technologies with molecular biology to explore fundamental questions about life and develop practical applications. Ph.D. from The University of Tokyo (1998) Professor, Hokkaido University (2022-present) Visiting Professor, Nara Institute of Science and Technology (2022) Vice Director, Osaka University SANKEN (2020-2022) Research Interests: Focus on Singularity Biology to study outlier cells' impact on biological systems, trans-scale imaging technologies (e.g., AMATERAS 3.0), and autoluminescent plants for sustainable lighting. Key methodologies include fluorescent/bioluminescent protein development and super-resolution imaging. Publication Trends: Recent works span cellular thermodynamics , water quality monitoring , synaptic plasticity , and trans-scale analytical systems . Collaborative projects address kidney injury mechanisms, plant biotechnology, and medical diagnostics. Scientific Recognition: 44th Shimadzu Prize (2024) 15th Nakatani Award Grand Prize (2023) Japanese Society of Microscopy Award (2020) 38th Japanese Society for Bioimaging Research Paper Award (2023) Grants & Collaborations: Recipient of JST ERATO grants and a Takeda Science Foundation grant (2021) for trans-scale life imaging. Collaborates with RIKEN, JST PRESTO, Health Sciences University of Hokkaido, and Kyushu Institute of Technology. Lab Overview: The Nagai Lab maintains active international partnerships (Indonesia University, Emory University) and hosts students through Osaka University's Frontier Bio program. Technical staff and research associates support projects in bioluminescent reporter systems and cellular logic.

• Virology
• Medical Microbiology
• Infectious Diseases
• +3 more

Nicola Clementi serves as an Associate Professor of Medical Microbiology and Virology at Vita-Salute San Raffaele University in Milan, Italy, with active clinical and research affiliation at San Raffaele Scientific Institute (IRCCS). His academic credentials include Board Certification in Medical Microbiology and Virology (2010) from Vita-Salute San Raffaele University and a Master's degree in Biological Sciences (2006) from Università Politecnica delle Marche, Ancona. His educational background features: Master of Biological Sciences, Università Politecnica delle Marche, Ancona, Italy (2006) Board Certification in Medical Microbiology and Virology, Vita-Salute San Raffaele University, Milan, Italy (2010) Clementi's research centers on clinical virology and medical microbiology with emphasis on bacterial and viral pathogen dynamics. His work spans sexually transmitted infections (LGV, gonorrhea), emerging viral outbreaks (mpox, SARS-CoV-2), neonatal viral hepatitis , and microbiome-immune interactions in immunotherapy. He employs epidemiological surveillance, mutational profiling, and clinical cohort analysis to address antimicrobial resistance trends and therapeutic efficacy challenges within Italian healthcare settings. His 2024 publications reveal a focus on urgent public health threats through high-impact clinical studies. Key trends include optimizing antibiotic regimens for STIs, investigating immunological mechanisms in viral hepatitis, analyzing SARS-CoV-2 mutational responses to ribavirin therapy, and exploring microbiome modulation to reduce immunotherapy toxicity. The work heavily leverages Italian patient cohorts (Lombardy region) and demonstrates interdisciplinary approaches bridging virology, bacteriology, and immunology. No scientific awards are documented in the provided source material. While formal student lists and grant details are absent from the scraped data, his editorial roles and publication volume suggest active academic mentoring. Clementi serves as Review Editor for Virology at Frontiers in Microbiology and Guest Associate Editor for Experimental Pharmacology at Frontiers in Pharmacology, indicating leadership in scholarly peer review despite no explicit grant mentions. He operates within San Raffaele Scientific Institute (IRCCS) research ecosystem, evidenced by co-authorship with clinicians and microbiologists from this tertiary hospital. His network includes collaborators like Gabriel Siracusano (IRCCS) and Mauro Pistello (University of Pisa), with 46 active professional connections reflecting engagement in Italy's infectious disease community.

David AndesView profile

Professor

• Antimicrobial Resistance
• Antifungal Drug Resistance
• Medical Mycology
• +7 more

David Andes, MD, is a Professor at the University of Wisconsin–Madison, holding appointments in the Department of Medicine and the Department of Medical Microbiology & Immunology within the School of Medicine and Public Health. He holds the William A. Craig Endowed Professorship and serves as Chief of the Division of Infectious Diseases. Dr. Andes directs the NIH-funded Wisconsin Antimicrobial Drug Discovery and Development Center of Excellence and leads a multidisciplinary research team focused on antimicrobial resistance. University: University of Wisconsin–Madison School: School of Medicine and Public Health Department: Department of Medicine Secondary Appointment: Department of Medical Microbiology & Immunology Rank: Professor Endowment: William A. Craig Endowed Professor Leadership: Chief, Division of Infectious Diseases Dr. Andes’ research focuses on understanding and combating antimicrobial drug resistance, particularly in fungal pathogens. His work spans from molecular mechanisms of resistance in biofilms to clinical trials and epidemiology. He employs in vivo infection models, pharmacokinetic/pharmacodynamic modeling, and drug development strategies to define optimal antimicrobial dosing and identify new therapeutic targets. His research has directly informed clinical guidelines for managing resistant infections. The 15 most recent publications highlight a strong focus on antifungal resistance, fungal biofilms, pathogenesis of Candida species (including C. albicans and C. auris), extracellular vesicles, therapeutic drug monitoring, and the development of clinical guidelines. These works appear in top journals such as Science , Nature Microbiology , Clinical Infectious Diseases , and The Lancet Infectious Diseases , reflecting the high impact and translational nature of his research. Dr. Andes has received numerous honors, including: National Institutes of Health Mentored Clinical Scientist Development Award Top 1% Highly Cited Researcher (Web of Science) Billy Cooper Award, Medical Mycological Society of the Americas University of Wisconsin Puestow and Rankin Research Awards American Society of Health-System Pharmacy Innovation Award He is a Fellow of the Infectious Diseases Society of America, the American Academy of Microbiology, and the American Association for the Advancement of Science. He serves on the editorial boards of ten journals, including Journal of Infectious Diseases and Antimicrobial Agents and Chemotherapy , and has been a member of influential committees such as the Clinical Laboratory Standards Institute Antifungal Committee and the Mycoses Study Group Steering Committee. He has trained numerous students and postdoctoral researchers through his lab and educational programs like the Molecular Mycology Training Course at MBL. His research is continuously funded by the NIH and FDA, supporting multiple active projects in antimicrobial discovery and development. Dr. Andes leads the Andes Research Lab, which investigates fungal biofilm resistance, in vivo pathogenesis, and drug development. The lab utilizes animal models, molecular biology, and pharmacodynamic approaches to study resistance mechanisms and evaluate novel therapeutics. The team includes scientists, researchers, and clinical collaborators working on interdisciplinary projects aimed at addressing the global crisis of antimicrobial resistance.

• Prostate Cancer
• Cancer Biology
• Translational Research
• +7 more

Professor Bill Watson is a Full Professor of Cancer Biology at the University College Dublin, School of Medicine , where he serves as Head of Pathology and Director of the Biomedical Health and Life Science BSc program. With a PhD in Biochemistry (University College Cork, 1995) and post-doctoral training at the University of Toronto, he has led translational research in prostate cancer since returning to UCD in 1997. His work focuses on biomarker discovery, therapy resistance mechanisms, and clinical decision tools through the Prostate Cancer Research Consortium and iPROSPECT collaborations. Education: BSc (University College Dublin), PhD (Royal College of Surgeons in Ireland), Post-Doctoral Research Fellow (Toronto General Hospital) His research integrates genomic, epigenetic, and proteomic biomarkers to improve prostate cancer stratification and treatment selection, as demonstrated in the Movember Global Action Plan and ToPCaP initiatives. Recent studies include validating a six-gene MCRS signature for biopsy-based prognostics (2025) and developing beta mixture models for DNA methylation analysis (2024). Scientific Awards include the Alton Prize (2000), Presidents Awards for Teaching (2000, 1998), and Young Investigator Award (1995). He has received grants such as the UCD Equip Scheme (2021) and Molecular Therapeutics for Cancer (2009-2015) . Professional Leadership: Irish Association for Cancer Research (President 2014-2017), Cancer Trials Ireland (Chair of Translational DSSG 2014-present), and Royal Academy of Medicine in Ireland (Fellow since 2006)